Supplier
Mayo Clinic Health System-Northwest Wisconsin Region, INC.
Mayo Clinic Health System-Northwest Wisconsin Region, INC. was paid $7.81M by Medicaid between Jan 2018 and Dec 2024, across 164 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-NORTHWEST WISCONSIN REGION, INC.
BARRON, WI 54812
BARRON, WI 54812
33aNPI1740239557assigned 05/09/2006
33bProvider typePharmacy
28Total paid$7.81M
24GClaims254,846
24DCodes billed164
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pharmacy providers in Wisconsin
Rank by total paid#3 of 98
Median peer was paid$4K
This provider vs. median2,221×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BORTNEM, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,109 | $682K | |
| 2019 | 34,661 | $845K | |
| 2020 | 30,242 | $970K | |
| 2021 | 39,366 | $1.22M | |
| 2022 | 38,724 | $1.46M | |
| 2023 | 40,964 | $1.28M | |
| 2024incomplete | 35,780 | $1.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 7,957 | 6,387 | $1.41M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 8,639 | 5,687 | $1.07M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 2,763 | 2,329 | $1.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 7,639 | 5,446 | $928K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.3% | 21,412 | 15,472 | $490K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 2,108 | 1,861 | $380K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 1,359 | 1,200 | $325K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 1,588 | 1,399 | $305K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 1,745 | 1,255 | $258K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.9% | 13,761 | 9,443 | $145K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 570 | 511 | $124K |
| 87631 | 1.3% | 1,336 | 1,235 | $105K |
152 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 9,445 | $86K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 907 | $85K |
| 80053 | Comprehensive metabolic panel | <1% | 10,340 | $69K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,247 | $67K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 974 | $64K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,956 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,544 | $55K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,209 | $41K |
| 11721 | <1% | 1,091 | $37K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,047 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,096 | $34K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,374 | $34K |
| 80061 | Lipid panel | <1% | 3,107 | $25K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,423 | $25K |
| 73630 | <1% | 987 | $24K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,754 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 82 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,290 | $20K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 103 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 448 | $17K |
| 83605 | <1% | 2,792 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,085 | $14K |
| 84484 | <1% | 1,965 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 861 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 570 | $13K |
| 81025 | <1% | 1,785 | $12K | |
| 83880 | <1% | 1,176 | $11K | |
| 86140 | <1% | 3,752 | $11K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 67 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,899 | $10K |
| 83690 | <1% | 2,312 | $10K | |
| 81001 | <1% | 5,053 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 121 | $8K |
| 85610 | <1% | 7,104 | $8K | |
| 87480 | <1% | 526 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,962 | $8K |
| 87660 | <1% | 526 | $8K | |
| 87510 | <1% | 526 | $8K | |
| 73564 | <1% | 354 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 450 | $7K |
| 85027 | <1% | 1,864 | $7K | |
| 83735 | <1% | 2,405 | $7K | |
| 80050 | General health panel | <1% | 276 | $7K |
| 87103 | <1% | 916 | $7K | |
| 87040 | <1% | 1,711 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 434 | $6K |
| 80306 | <1% | 437 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 690 | $5K |
| 73030 | <1% | 239 | $5K | |
| 82570 | <1% | 1,426 | $4K | |
| 82043 | <1% | 1,182 | $4K | |
| 20610 | <1% | 55 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,208 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,497 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,834 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,218 | $3K |
| 81003 | <1% | 2,179 | $3K | |
| 82565 | <1% | 1,270 | $3K | |
| 82077 | <1% | 335 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 206 | $3K |
| 85379 | <1% | 503 | $2K | |
| 86850 | <1% | 636 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 222 | $2K |
| 82947 | <1% | 810 | $2K | |
| 84702 | <1% | 168 | $2K | |
| 82248 | <1% | 873 | $2K | |
| 97162 | <1% | 253 | $2K | |
| 73502 | <1% | 77 | $2K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 709 | $2K |
| 76801 | <1% | 12 | $2K | |
| 87077 | <1% | 478 | $2K | |
| 73610 | <1% | 72 | $2K | |
| 84450 | <1% | 396 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 235 | $1K |
| 73110 | <1% | 50 | $1K | |
| 91322 | <1% | 180 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,824 | $1K |
| 72100 | <1% | 51 | $999.42 | |
| 99307 | <1% | 86 | $941.69 | |
| 90662 | <1% | 505 | $872.97 | |
| 87186 | <1% | 328 | $868.39 | |
| 90715 | <1% | 48 | $861.61 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 46 | $845.55 |
| 82948 | <1% | 254 | $788.03 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 562 | $780.77 |
| 82803 | <1% | 56 | $763.76 | |
| 86900 | <1% | 391 | $745.17 | |
| 86901 | <1% | 391 | $745.17 | |
| 99443 | <1% | 38 | $637.25 | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $613.30 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 116 | $585.19 |
| 99442 | <1% | 65 | $558.04 | |
| 84153 | <1% | 42 | $555.01 | |
| 90686 | <1% | 319 | $499.82 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $496.78 |
| 76376 | <1% | 12 | $479.58 | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 24 | $478.56 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 115 | $434.40 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,432 | $425.09 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $401.01 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $401.01 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,831 | $341.03 |
| 36416 | <1% | 1,821 | $337.79 | |
| 80143 | <1% | 29 | $335.52 | |
| 85018 | <1% | 184 | $327.24 | |
| 90480 | <1% | 167 | $279.35 | |
| 88142 | <1% | 12 | $275.70 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 14 | $234.36 |
| 85652 | <1% | 137 | $220.56 | |
| 83655 | <1% | 14 | $181.17 | |
| 84439 | <1% | 32 | $161.82 | |
| 99441 | <1% | 26 | $150.98 | |
| 80179 | <1% | 14 | $139.44 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 261 | $108.97 |
| 84460 | <1% | 41 | $108.34 | |
| J2704 | Injection, propofol, 10 mg | <1% | 664 | $105.01 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 953 | $81.12 |
| 90656 | <1% | 48 | $67.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,733 | $53.54 |
| 0764T | <1% | 119 | $49.79 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,073 | $39.38 |
| J3490 | Unclassified drugs | <1% | 311 | $36.67 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 619 | $36.42 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 209 | $34.68 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 39 | $31.29 |
| 87070 | <1% | 29 | $23.71 | |
| 90677 | <1% | 15 | $23.33 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 129 | $22.63 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 127 | $18.24 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 27 | $17.80 |
| 82728 | <1% | 28 | $14.08 | |
| 0124A | <1% | 52 | $10.72 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 13 | $6.56 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 82 | $5.71 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 69 | $3.91 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 28 | $3.16 |
| 0004A | <1% | 46 | $2.27 | |
| 0134A | <1% | 19 | $2.02 | |
| 0054A | <1% | 51 | $1.11 | |
| 96376 | <1% | 73 | $0.24 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 89 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 43 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 29 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 17 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,791 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 25 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 631 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 18 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 18 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 16 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBORTNEM, MARK (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.